Target

CD19

B-lymphocyte antigen CD19

362open trials
542trials in total
335publications
0researchers

Diseases

Acute lymphoblastic leukaemia195 trials
Childhood cancers163 trials
Lupus (SLE)103 trials
Chronic lymphocytic leukaemia75 trials
Diffuse large B-cell lymphoma75 trials
Systemic sclerosis (scleroderma)57 trials
Follicular lymphoma51 trials
Mantle cell lymphoma37 trials
ANCA-associated vasculitis36 trials
Multiple myeloma33 trials
Rheumatoid arthritis18 trials
Multiple sclerosis15 trials
Sjögren's disease15 trials
Acute myeloid leukemia14 trials
Myasthenia gravis14 trials
Hodgkin lymphoma13 trials
Myelodysplastic syndromes10 trials
IgA nephropathy9 trials
Neuromyelitis optica (NMOSD)6 trials
CIDP (chronic inflammatory demyelinating polyneuropathy)5 trials

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
1 Dec 2027· PHASE1 · WITHDRAWN· CTGOV
Trial
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
1 Aug 2027· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Universal CAR-T Cells Targeting Multiple Myeloma
30 Jun 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
CD19/22 Bi-specific CAR-T Cell Therapy
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
CD19/70 Bi-specific CAR-T Cell Therapy
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR-T Cells Targeting B Cell Lymphomas
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
1 May 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
1 Apr 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
3 Feb 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
1 Feb 2027· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
1 Jan 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
4SCAR19U T Cells Targeting B Cell Malignancies
31 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
CD19-B Cell Depletion in PAIS-ME/CFS Patients
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
1 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Depletion of CD19-positive B-cells and dexamethasone premedication may result in immune suppression in patients with B-precursor acute lymphoblastic leukemia after consolidation treatment with blinatumomab.
5 Nov 2026· Haematologica· PUBMED
Publication
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.
3 Nov 2026· Blood cancer discovery· PUBMED
Publication
CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All.
3 Nov 2026· Blood cancer discovery· PUBMED
Publication
RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T-Resistant Large B-cell Lymphomas.
3 Nov 2026· Blood cancer discovery· PUBMED
Trial
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
1 Nov 2026· PHASE1 · RECRUITING· CTGOV
Trial
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
1 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
1 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.
1 Nov 2026· The Lancet. Oncology· PUBMED
Publication
Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies.
1 Nov 2026· The Lancet. Rheumatology· PUBMED
Publication
Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
1 Nov 2026· Hematological oncology· PUBMED
Trial
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
31 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTIS
Trial
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
30 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Long-term remission of severe psoriasis following CD19-directed chimeric antigen receptor T-cell therapy for follicular lymphoma.
27 Oct 2026· Clinical and experimental dermatology· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error